Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-01-11
2009-11-24
O'Sullivan, Peter G (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253070, C514S312000, C514S367000, C544S128000, C544S363000, C546S157000, C548S179000, C548S180000
Reexamination Certificate
active
07622467
ABSTRACT:
The invention provides novel β2adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.
REFERENCES:
patent: 3875233 (1975-04-01), Bastian et al.
patent: 4021485 (1977-05-01), Schromm et al.
patent: 4894219 (1990-01-01), Baker et al.
patent: 4992474 (1991-02-01), Skidmore et al.
patent: 5223614 (1993-06-01), Schromm et al.
patent: 5434304 (1995-07-01), Trofast et al.
patent: 5750701 (1998-05-01), Beeley et al.
patent: 6265581 (2001-07-01), Bell et al.
patent: 6268533 (2001-07-01), Gao et al.
patent: 6541669 (2003-04-01), Moran et al.
patent: 6576793 (2003-06-01), Moran et al.
patent: 6653323 (2003-11-01), Moran et al.
patent: 6670376 (2003-12-01), Moran et al.
patent: 6747043 (2004-06-01), Moran et al.
patent: 6759398 (2004-07-01), Biggadike
patent: 6825220 (2004-11-01), Jesudason et al.
patent: 6949568 (2005-09-01), Moran et al.
patent: 7060712 (2006-06-01), Axt et al.
patent: 7125892 (2006-10-01), Moran et al.
patent: 7317023 (2008-01-01), McKinnell et al.
patent: 2002/0019378 (2002-02-01), Angell et al.
patent: 2002/0022625 (2002-02-01), Walland et al.
patent: 2002/0143034 (2002-10-01), Taniguchi et al.
patent: 2003/0229058 (2003-12-01), Moran et al.
patent: 2004/0059116 (2004-03-01), Moran et al.
patent: 2004/0063755 (2004-04-01), Moran et al.
patent: 2004/0157830 (2004-08-01), Biggadike et al.
patent: 2004/0167167 (2004-08-01), Mammen et al.
patent: 2004/0180876 (2004-09-01), Biggadike et al.
patent: 2004/0186080 (2004-09-01), Moran et al.
patent: 2004/0224982 (2004-11-01), Axt et al.
patent: 2004/0242890 (2004-12-01), Coe et al.
patent: 2004/0248985 (2004-12-01), Stergiades et al.
patent: 2005/0075271 (2005-04-01), Linsell et al.
patent: 2005/0113411 (2005-05-01), Linsell et al.
patent: 2005/0272769 (2005-12-01), Linsell
patent: 2006/0019991 (2006-01-01), McKinnell et al.
patent: 2006/0058530 (2006-03-01), Linsell et al.
patent: 2007/0225329 (2007-09-01), Moran et al.
patent: 2008/0113981 (2008-05-01), McKinnell et al.
patent: 849 794 (1977-04-01), None
patent: 550 768 (1972-02-01), None
patent: 0 233 686 (1987-08-01), None
patent: 0147 719 (1989-07-01), None
patent: 0 196 849 (1996-10-01), None
patent: 1040724 (1966-09-01), None
patent: 1 463 219 (1977-02-01), None
patent: 52-83379 (1977-07-01), None
patent: 52-83619 (1977-07-01), None
patent: WO 99/64035 (1999-12-01), None
patent: WO 00/75114 (2000-12-01), None
patent: WO 01/07026 (2001-02-01), None
patent: WO 01/42193 (2001-06-01), None
patent: WO 02/00622 (2002-01-01), None
patent: WO 03/024439 (2003-03-01), None
patent: WO 03/042164 (2003-05-01), None
patent: WO 03/072539 (2003-09-01), None
patent: WO 03/091204 (2003-11-01), None
patent: WO 2004/002939 (2004-01-01), None
patent: WO 2004/016578 (2004-02-01), None
patent: WO 2004/089892 (2004-10-01), None
U.S. Appl. No. 10/627,555, filed May 8, 2003, Linsell et al.
U.S. Appl. No. 10/946,544, filed Feb. 17, 2005, Linsell et al.
Bompart et al., “Synthesis of new β-blocking analogs of bevantolol”, Annales Pharmaceutiques Francaises, Volume Date 1984, 42(6), pp. 537-545 (1985) (In French with English abstract).
Bompart et al., “Synthesis of new β-blocker analogs of bevantolol or alprenolol”, Annales Pharmaceutiques Francaises, Volume Date 1987, 45(5), pp. 379-387 (1988) (In French with English abstract).
Deyrup et al., “Structure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the Beta2-adrenoceptor”, Naunyn-Schmiedeberg's Arch Pharmacol (1999) 359:168-177.
Isogaya et al., “Binding Pockets of the β1- and β2-Adrenergic Receptors for Subtype-Selective Agonists”), Molecular Pharmacology, vol. 56, pp. 875-885 (1999).
Milecki et al., “Carbostyril Derivatives Having Potent β-Adrenergic Agonist Properties”, J. Med. Chem, (1987), 30, 1563-1566.
Yokoi et al., “The Development of a Radioimmunoassay for Formoterol”, Life Sciences, (1983) vol. 33, No. 17, pp. 1665-1672.
Yoshizaki et al., “Sympathomimetic Amines Having a Carbostyril Nucleus”, J. Med. Chem., (1976), vol. 19, No. 9, pp. 1138-1142.
Jacobsen John R.
McKinnell Robert M.
Saito Daisuke R.
Trapp Sean G.
Hagenah Jeffrey A.
O'Sullivan Peter G
Saxon Roberta P.
Theravance Inc.
LandOfFree
Aryl aniline derivatives as β 2 adrenergic receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl aniline derivatives as β 2 adrenergic receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl aniline derivatives as β 2 adrenergic receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4094565